Ankylosing Spondylitis: Recent Developments in Treatment
June 17, 2011|Family Medicine
Author and Disclosure Information
EXPERT ANALYSIS FROM THE CONGRESS OF CLINICAL RHEUMATOLOGY
However, while the response rate was significantly higher than with placebo, the relative change in BASDAI50 was relatively modest and not of the same magnitude typically seen with anti-TNF drugs, he said.
"So I think the jury is still out on the anti-IL17," he concluded.
Dr. Inman disclosed that he is a consultant for Abbott Laboratories, Merck , Pfizer, and Sanofi-Aventis.
